Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
miércoles, septiembre 02
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
NeoGenomics Inc
NEO
NASDAQ
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$17.45
-0.46
-2.57%
al cierre: Aug 31, 5:00 PM EST
$17.36
-0.55
-3.05%
Premercado: 5:19 AM EST
Get Report
Panorámica general
Noticias
Previsión de beneficios
Eventos
Precios objetivo
Finanzas
Sentimiento
Propiedad
Comparar
Opciones
Informe de acciones
NeoGenomics Financials
NeoGenomics (NEO) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
NeoGenomics Raises FY2026 Sales Guidance from $797.000M-$803.000M to $802.000M-$806.000M vs $800.433M Est
NeoGenomics (NASDAQ:NEO) raises FY2026 sales outlook from $797.000 million-$803.000 million to $802.000 million-$806.000 million vs $800.433 million estimate.
Benzinga Newsdesk
PRO
NeoGenomics Q2 Adj. EPS $0.05 Beats $0.03 Estimate, Sales $202.000M Beat $196.997M Estimate
NeoGenomics (NASDAQ:NEO) reported quarterly earnings of $0.05 per share which beat the analyst consensus estimate of $0.03 by 66.67 percent. This is a 66.67 percent increase over earnings of $0.03 per share from the
Benzinga Newsdesk
Earnings Scheduled For May 12, 2026
Benzinga Insights
PRO
NeoGenomics Raises FY2026 Sales Guidance from $793.000M-$801.000M to $797.000M-$803.000M vs $796.641M Est
NeoGenomics (NASDAQ:NEO) raises FY2026 sales outlook from $793.000 million-$801.000 million to $797.000 million-$803.000 million vs $796.641 million estimate.
Benzinga Newsdesk
PRO
NeoGenomics Q1 Adj. EPS $0.01, Inline, Sales $186.672M Beat $184.509M Estimate
NeoGenomics (NASDAQ:NEO) reported quarterly earnings of $0.01 per share which met the analyst consensus estimate. The company reported quarterly sales of $186.672 million which beat the analyst consensus estimate of
Benzinga Newsdesk
Earnings Scheduled For April 28, 2026
Benzinga Insights
Privacy Manager